DLH Wins FEMA Contract for COVID-19 Vaccination and Testing Services Throughout Alaska
October 14 2021 - 8:00AM
DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a
leading provider of innovative health research, services, and
solutions to federal agencies, today announced that it has been
awarded a contract to provide experienced medical personnel to
support COVID-19 community testing and collection, vaccination, and
monoclonal antibody therapy throughout the state of Alaska. The
award complements a separate contract to provide medical
countermeasures and emergency medical support to Alaska as the
state responds to an increase in COVID-19 cases, which DLH
announced in mid-September.
This competitive award, procured under a Federal Emergency
Management Agency (“FEMA”) contract to provide support for states
seeking medical support during the COVID-19 pandemic, has a ceiling
value of $20 million for the 90-day base period. It provides for
three one-month optional extensions after the initial period of
performance. As the prime contractor, DLH will provide the
emergency medical logistics coordination for the healthcare team
fielded by its subcontractor, which will be responsible for a
significant percentage of the services rendered.
“DLH is proud of our expanding relationship with the state of
Alaska, and we are well prepared for this opportunity to provide
additional COVID-19 response support activities,” said Kevin
Wilson, president of DLH’s Health & Logistics Services
operating unit. “Vaccination, testing, and monoclonal antibody
treatment are key tools in the battle against this pandemic, and
our team will work swiftly to ensure the skilled staff are in place
to provide Alaskans with these vital countermeasures.”
Under this contract, DLH will continue to leverage its
relationship with a nationally recognized temporary medical
staffing firm to place experienced support personnel in communities
throughout the state. These healthcare professionals will augment
the existing staff already providing emergency medical support
services in Alaska.
“Our company continues to utilize its healthcare delivery
expertise in support of the national response to COVID-19,” added
Zach Parker, President and CEO of DLH. “Ensuring the efficient
distribution and safe administration of medical countermeasures
such as testing, vaccination and therapeutics during public health
emergencies is vitally important, and DLH will draw upon its
relevant experience to deliver results for the people of
Alaska.”
About DLH:
DLH delivers improved health and readiness solutions for federal
programs through research, development, and innovative care
processes. The Company’s experts in public health, performance
evaluation, and health operations solve the complex problems faced
by civilian and military customers alike, leveraging digital
transformation, artificial intelligence, advanced analytics,
cloud-based applications, telehealth systems, and more. With over
2,200 employees dedicated to the idea that “Your Mission is Our
Passion,” DLH brings a unique combination of government sector
experience, proven methodology, and unwavering commitment to public
health to improve the lives of millions. For more information,
visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995:This press release may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
relate to future events or DLH`s future financial performance. Any
statements that refer to expectations, projections or other
characterizations of future events or circumstances or that are not
statements of historical fact (including without limitation
statements to the effect that the Company or its management
“believes”, “expects”, “anticipates”, “plans”, “intends” and
similar expressions) should be considered forward looking
statements that involve risks and uncertainties which could cause
actual events or DLH’s actual results to differ materially from
those indicated by the forward-looking statements. Forward-looking
statements in this release include, among others, statements
regarding estimates of future revenues, operating income, earnings
and cash flow. These statements reflect our belief and assumptions
as to future events that may not prove to be accurate. Our actual
results may differ materially from such forward-looking statements
made in this release due to a variety of factors, including: the
outbreak of the novel coronavirus (“COVID-19”), including the
measures to reduce its spread, and its impact on the economy and
demand for our services, are uncertain, cannot be predicted, and
may precipitate or exacerbate other risks and uncertainties; the
risk that we will not realize the anticipated benefits of our
recent or any future acquisition; the challenges of managing larger
and more widespread operations resulting from our recent
acquisition; contract awards in connection with re-competes for
present business and/or competition for new business; compliance
with new bank financial and other covenants; changes in client
budgetary priorities; government contract procurement (such as bid
and award protests, small business set asides, loss of work due to
organizational conflicts of interest, etc.) and termination risks;
the ability to successfully integrate the operations our recent
acquisition and of any future acquisitions; and other risks
described in our SEC filings. For a discussion of such risks and
uncertainties which could cause actual results to differ from those
contained in the forward-looking statements, see “Risk Factors” in
the Company’s periodic reports filed with the SEC, including our
Annual Report on Form 10-K for the fiscal year ended September 30,
2020, as well as subsequent reports filed thereafter. The
forward-looking statements contained herein are not historical
facts, but rather are based on current expectations, estimates,
assumptions and projections about our industry and business. Such
forward-looking statements are made as of the date hereof and may
become outdated over time. The Company does not assume any
responsibility for updating forward-looking statements, except as
may be required by law.
CONTACT:
INVESTOR RELATIONS |
Contact: Chris Witty |
Phone: 646-438-9385 |
Email: cwitty@darrowir.com |
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Apr 2023 to Apr 2024